South Africa included in Gates-led clinical trial of new TB vaccine hailed as potential game-changer

A Phase 3 clinical trial for M72, a new candidate vaccine against pulmonary tuberculosis will be conducted in South Africa. The head of Global Health at the Bill & Melinda Gates Foundation, Dr Trevor Mundel, said this week that they were very optimistic that it would be an effective and safe vaccine. However, this will be determined by the success of the Phase 3 trials.